NCT07912983 Metabolomic Biomarkers of Myotonic Dystrophy
| NCT ID | NCT07912983 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Myotonic Dystrophy Type 1 |
| Study Type | OBSERVATIONAL |
| Enrollment | 64 participants |
| Start Date | 2026-10-26 |
| Primary Completion | 2030-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 64 participants in total. It began in 2026-10-26 with a primary completion date of 2030-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of myotonic dystrophy by examining a urine sample and a blood sample, and performing muscle function testing. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human myotonic dystrophy.
Eligibility Criteria
Inclusion Criteria: * Individuals with myotonic dystrophy * Individuals without myotonic dystrophy * Ages 14 years and older Exclusion Criteria: * State of immunosuppression * Coagulopathy * Use of anticoagulants within 60 days prior to blood draw
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07912983 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Myotonic Dystrophy Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07912983 currently recruiting?
Yes, NCT07912983 is actively recruiting participants. Contact the research team at tshahraki@mgh.harvard.edu for enrollment information.
Where is the NCT07912983 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07912983 clinical trial?
NCT07912983 is sponsored by Massachusetts General Hospital. The trial plans to enroll 64 participants.